OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New heart drug shows promise in major trial for stiff heart muscle disease
Disease control CompletedThis study tested a new medicine called aficamten in 282 adults with a type of heart disease that makes the heart muscle too thick and blocks blood flow. The goal was to see if the drug helps people breathe easier and feel better during exercise compared to a placebo. The trial w…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated May 26, 2026 09:57 UTC
-
Real-World data shows how mavacamten helps patients with thick heart muscle
Disease control CompletedThis study looked at 163 adults with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is too thick and blocks blood flow) who were treated with the drug mavacamten. Researchers collected information from medical records to see how patients were doing in…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 26, 2026 09:52 UTC
-
Heart drug mavacamten shows promise in Real-World HCM patients
Disease control CompletedThis study tested the drug mavacamten in 222 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM), which makes the heart muscle thick and blocks blood flow. Researchers compared patients who got mavacamten to those on standard treatment, measu…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital • Aim: Disease control
Last updated May 26, 2026 09:51 UTC
-
Heart drug mavacamten shows Real-World promise in canadian study
Disease control CompletedThis study reviewed medical charts of 115 adults in Canada who started taking mavacamten for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens and blocks blood flow. Researchers wanted to see how the drug improved symptoms and heart funct…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM)
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 22, 2026 14:03 UTC